.png)
Agenzia Italiana del Farmaco
Direct communication with healthcare professionals on suspension of the marketing authorisations of medicinal products containing hydroxyprogesterone caproate - Direct communication with healthcare professionals on suspension of the marketing authorisations of medicinal products containing hydroxyprogesterone caproate
Direct communication with healthcare professionals on suspension of the marketing authorisations of medicinal products containing hydroxyprogesterone caproate
Following the conclusion of the review, a DHPC was prepared regarding the suspension of the marketing authorization for medicinal products containing hydroxyprogesterone caproate.
The benefit/risk balance of medicinal products containing 17-OHPC is no longer considered favorable in all authorized indications. The marketing authorizations for these medicines will be suspended and they will no longer be available.
Published on: 17 July 2024
Oggi si celebra il #WorldAutismAwarenessDay.
🔵 L'Agenzia Italiana del Farmaco sostiene la Giornata...
Vai al post →
Jelena Ivanovic, dirigente medico dell’Ufficio Procedure Europee di #HTA di #AIFA, è stata eletta Co...
Vai al post →
Biosimilari: webinar AIFA su terzo Position Paper
La Commissione Scientifica ed Economica (CSE) di ...
Vai al post →
🎙️ Il Presidente #AIFA intervistato da @presadirettarai sulle false terapie a base di cellule stami...
Vai al post →
💛 28 marzo 2026 – Giornata Mondiale dell’Endometriosi 💛
#AIFA si illumina di giallo per accendere...
Vai al post →
🤝🌍 A Roma i lavori dell’EDQM Borderline Products Network Meeting
💬 Il meeting, ospitato da #AIFA...
Vai al post →
